Status:

ACTIVE_NOT_RECRUITING

A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors

Lead Sponsor:

Genmab

Collaborating Sponsors:

BioNTech SE

Conditions:

Malignant Solid Tumor

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

This study evaluating GEN1042 will include multiple parts. In this study, GEN1042 alone (phase 1a) or GEN1042 in combination with other anticancer drug(s) (phase 1b) will be evaluated in Japanese part...

Detailed Description

This is an open-label, trial to evaluate the safety and tolerability, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of GEN1042 in Japanese participants with malignant solid tumors. T...

Eligibility Criteria

Inclusion

  • Key
  • Must have measurable disease according to RECIST v1.1.
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.
  • Acceptable organ and bone marrow function.
  • Participant must have a life expectancy of at least 3 months.
  • Key

Exclusion

  • Has clinically significant toxicities from previous anticancer therapies.
  • Has rapidly progressing disease.
  • Has a history of noninfectious pneumonitis/interstitial lung disease.
  • Has a history of liver disease.
  • Has had an allogeneic tissue/solid organ transplant or autologous or allogeneic bone marrow transplant, or stem cell rescue within 3 months prior to the first dose of GEN1042.
  • Has any history of intracerebral arteriovenous malformation, cerebral aneurysm, or progressive brain metastases or stroke.
  • Has had major surgery within 4 weeks before Screening.
  • NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Key Trial Info

Start Date :

November 24 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

November 28 2026

Estimated Enrollment :

42 Patients enrolled

Trial Details

Trial ID

NCT06057038

Start Date

November 24 2023

End Date

November 28 2026

Last Update

January 6 2026

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

National Cancer Center East

Kashiwa, Japan

2

National Cancer Center Hospital

Tokyo, Japan

3

Tokyo Medical University Hospital

Tokyo, Japan